Search Results 421-430 of 11131 for ANCA vasculitis

  1. Vascular centers - Doctors - Mayo Clinic

    Cooper, Jr., M.D.. Cardiologist. Jacksonville, FL; Rochester, MN. Areas of focus: Heart failure, Amyloidosis, Myocarditis, Pericarditis, Vasculitis, Sarcoidosis ...

  2. Brain aneurysm - Doctors and departments - Mayo Clinic

    cerebral hemorrhage, Brain aneurysm, CNS vasculitis, Embolic stroke. Show more areas of focus for Irene Meissner, M.D.. Fredric B ...

  3. Strategy To Prevent The Onset Of Clinically-Apparent Rheumatoid Arthritis

    ... vasculitis. Patients with mild/moderate crystalline arthropathies do not need to be excluded. Prior or current systemic treatment with DMARDs ...

  4. CT scan - Doctors & Departments - Mayo Clinic

    Vasculitis · Ventricular fibrillation · Vertebral tumor · Vocal cord paralysis · Vulvar cancer · Whiplash · Wilms tumor · Wilson's disease · Wrist pain ...

  5. Brain aneurysm - Doctors and departments - Mayo Clinic

    cerebral hemorrhage, Brain aneurysm, CNS vasculitis, Embolic stroke. Show more areas of focus for Irene Meissner, M.D.. Fredric B ...

  6. Cardiovascular Medicine - Doctors - Mayo Clinic

    Anca Chiriac, M.D., Ph.D. Cardiac Electrophysiologist. Jacksonville, FL. Areas of focus: Pacemaker insertion, Implantable ...

  7. Brain aneurysm - Doctors and departments - Mayo Clinic

    cerebral hemorrhage, Brain aneurysm, CNS vasculitis, Embolic stroke. Show more areas of focus for Irene Meissner, M.D.. Fredric B ...

  8. Brain aneurysm - Doctors and departments - Mayo Clinic

    cerebral hemorrhage, Brain aneurysm, CNS vasculitis, Embolic stroke. Show more areas of focus for Irene Meissner, M.D.. Fredric B ...

  9. Vascular centers - Doctors - Mayo Clinic

    Koster, M.D.. Internist; Rheumatologist. Rochester, MN. Areas of focus: Ultrasound, Giant cell arteritis, Takayasu's arteritis, Vasculitis, Granulomatosis with ...

  10. Relapse Prediction Following Discontinuation of Tocilizumab In Giant Cell Arteritis - Mayo Clinic

    ... vasculitis. Treated with tocilizumab (subcutaneous OR intravenous) for ≥ 12 months but < 48 months prior to study entry. In clinical remission (that is no ...